Legal & General Group’s Foghorn Therapeutics FHTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.2K Sell
2,985
-393
-12% -$2.16K ﹤0.01% 3093
2025
Q4
$18.2K Hold
3,378
﹤0.01% 3064
2025
Q3
$16.5K Sell
3,378
-170
-5% -$901 ﹤0.01% 3122
2025
Q2
$16.7K Buy
3,548
+842
+31% +$3.52K ﹤0.01% 3088
2025
Q1
$9.88K Hold
2,706
﹤0.01% 3174
2024
Q4
$12.8K Hold
2,706
﹤0.01% 3192
2024
Q3
$25.2K Sell
2,706
-118
-4% -$854 ﹤0.01% 2956
2024
Q2
$16.2K Buy
2,824
+815
+41% +$4.86K ﹤0.01% 3109
2024
Q1
$13.4K Hold
2,009
﹤0.01% 3134
2023
Q4
$13K Hold
2,009
﹤0.01% 3186
2023
Q3
$10K Sell
2,009
-500
-20% -$3.85K ﹤0.01% 3267
2023
Q2
$17.7K Buy
2,509
+287
+13% +$2.01K ﹤0.01% 3161
2023
Q1
$13.8K Hold
2,222
﹤0.01% 3150
2022
Q4
$14.2K Hold
2,222
﹤0.01% 3214
2022
Q3
$19K Hold
2,222
﹤0.01% 3217
2022
Q2
$30K Buy
2,222
+557
+33% +$7.19K ﹤0.01% 3113
2022
Q1
$25K Buy
1,665
+60
+4% +$823 ﹤0.01% 3174
2021
Q4
$37K Sell
1,605
-68
-4% -$977 ﹤0.01% 3097
2021
Q3
$23K Sell
1,673
-49
-3% -$543 ﹤0.01% 3223
2021
Q2
$18K Buy
1,722
+1,006
+141% +$11K ﹤0.01% 3325
2021
Q1
$9K Hold
716
﹤0.01% 3401
2020
Q4
$15K Buy
+716
New +$13.7K ﹤0.01% 3196

Other funds holding FHTX

Legal & General Group's FHTX Position: Q1 2026 in Review

Legal & General Group reduced its Foghorn Therapeutics (FHTX) stake by 12% in Q1 2026, selling an estimated $2.16K and leaving 2,985 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3093.

Legal & General Group first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $37K in Q4 2021. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Legal & General Group held 2,985 shares of Foghorn Therapeutics worth $14.2K as of Q1 2026.
  • Legal & General Group sold 393 Foghorn Therapeutics shares in Q1 2026, an estimated $2.16K.
  • Foghorn Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3093 holding.
  • Legal & General Group first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Legal & General Group's Foghorn Therapeutics position peaked at $37K in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.